Rachel Baum

Rachel Baum

Auto-generated profile, based on publicly available information

Rachel Baum

Department of Medicine, University of California, San Diego, La Jolla, Calif

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Clinical Immunology
Verified
Journal Article
Closed access
HWHannah H. Walford
Hannah H. Walford
SLSean J. Lund
Sean J. Lund
RBRachel E. Baum
Rachel E. Baum
AWAndrew A. White
Andrew A. White
CBChristopher M. Bergeron
Christopher M. Bergeron
TDTaylor A Doherty
Taylor A Doherty

1 March 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JCJinny E. Chang
Jinny E. Chang
TDTaylor A Doherty
Taylor A Doherty
RBRachel Baum
Rachel Baum
DBDavid Broide
David Broide

1 September 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
TDTaylor A Doherty
Taylor A Doherty
RBRachel Baum
Rachel Baum
RNRobert O. Newbury
Robert O. Newbury
TYTom Yang
Tom Yang
RDRanjan Dohil
Ranjan Dohil
SASeema Aceves
Seema Aceves

1 August 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SLSean J. Lund
Sean J. Lund
APAlex Portillo
Alex Portillo
KCKellen Cavagnero
Kellen Cavagnero
RBRachel E Baum
Rachel E Baum
LNLuay H. Naji
Luay H. Naji
TDTaylor A Doherty
Taylor A Doherty
Asthma is a complex disease that is promoted by dysregulated immunity and the presence of many cytokine and lipid mediators. Despite this, there is a paucity of data demonstrating the combined effects of multiple mediators in asthma pathogenesis. Group 2 innate lymphoid cells (ILC2s) have recently been shown to play important roles in the initiation of allergic inflammation; however, it is unclear whether lipid mediators, such as cysteinyl leukotrienes (CysLTs), which are present in asthma, could further amplify the effects of IL-33 on ILC2 activation and lung inflammation. In this article, we show that airway challenges with the parent CysLT, leukotriene C4 (LTC4), given in combination with low-dose IL-33 to naive wild-type mice, led to synergistic increases in airway Th2 cytokines, eosinophilia, and peribronchial inflammation compared with IL-33 alone. Further, the numbers of proliferating and cytokine-producing lung ILC2s were increased after challenge with both LTC4 and IL-33. Levels of CysLT1R, CysLT2R, and candidate leukotriene E4 receptor P2Y12 mRNAs were increased in ILC2s. The synergistic effect of LTC4 with IL-33 was completely dependent upon CysLT1R, because CysLT1R−/− mice, but not CysLT2R−/− mice, had abrogated responses. Further, CysLTs directly potentiated IL-5 and IL-13 production from purified ILC2s stimulated with IL-33 and resulted in NFAT1 nuclear translocation. Finally, CysLT1R−/− mice had reduced lung eosinophils and ILC2 responses after exposure to the fungal allergen Alternaria alternata. Thus, CysLT1R promotes LTC4- and Alternaria-induced ILC2 activation and lung inflammation. These findings suggest that multiple pathways likely exist in asthma to activate ILC2s and propagate inflammatory responses.

1 April 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
TDTaylor A Doherty
Taylor A Doherty
DSDavid Scott
David Scott
HWHannah H. Walford
Hannah H. Walford
NKNaseem Khorram
Naseem Khorram
SLSean Lund
Sean Lund
DBDavid H. Broide
David H. Broide

1 October 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
AKAlexander S. Kim
Alexander S. Kim
TDTaylor A Doherty
Taylor A Doherty
MKMaya R. Karta
Maya R. Karta
SDSudipta Das
Sudipta Das
RBRachel Baum
Rachel Baum
DBDavid H. Broide
David H. Broide